📰 High Acuity News
Page 8 - High Acuity News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from High Acuity. Real-time updates on events, politics, business and more.
July 8, 2023
Amedisys (NASDAQ:AMED – Free Report) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, FlyOnTheWall reports. Other research analysts have also issued research reports about the company. Barclays boosted their price target on Amedisys from $88.00 to $101.00 […]
July 7, 2023
StockNews.com started coverage on shares of Amedisys (NASDAQ:AMED – Free Report) in a research report report published on Monday morning. The brokerage issued a buy rating on the health services provider’s stock. Other research analysts also recently issued research reports about the stock. SVB Securities reduced their price target on shares of Amedisys from $96.00 […]
July 6, 2023
StockNews.com started coverage on shares of Amedisys (NASDAQ:AMED – Free Report) in a research note issued to investors on Monday morning. The firm issued a buy rating on the health services provider’s stock. AMED has been the topic of several other research reports. Truist Financial increased their price target on shares of Amedisys from $97.00 […]
July 6, 2023
A number of research firms have changed their ratings and price targets for Amedisys (NASDAQ: AMED): 7/6/2023 – Amedisys was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. 7/3/2023 – Amedisys is now covered by analysts at StockNews.com. They set a “buy” rating on the stock. 6/27/2023 […]
July 6, 2023
A number of research firms have changed their ratings and price targets for Amedisys (NASDAQ: AMED): 7/6/2023 – Amedisys was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. 7/3/2023 – Amedisys is now covered by analysts at StockNews.com. They set a “buy” rating on the stock. 6/27/2023 […]
July 5, 2023
Equities researchers at StockNews.com started coverage on shares of Amedisys (NASDAQ:AMED – Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating on the health services provider’s stock. AMED has been the subject of a number of other reports. Benchmark downgraded shares of Amedisys from a […]
July 5, 2023
/PRNewswire/ -- The Dungarvin organization, a group of companies providing community-based services for people with disabilities in 15 states, has announced a...
July 1, 2023
Benchmark lowered shares of Amedisys (NASDAQ:AMED – Free Report) from a buy rating to a hold rating in a research note released on Tuesday, The Fly reports. A number of other research analysts have also recently commented on AMED. Truist Financial upped their target price on Amedisys from $97.00 to $101.00 in a research note […]
July 1, 2023
Amedisys (NASDAQ:AMED – Free Report) had its price target increased by Truist Financial from $97.00 to $101.00 in a report released on Tuesday morning, The Fly reports. A number of other equities analysts also recently weighed in on AMED. Stephens reaffirmed an equal weight rating and issued a $103.00 price target on shares of Amedisys […]
July 1, 2023
Amedisys (NASDAQ:AMED – Free Report) had its price target boosted by Barclays from $88.00 to $101.00 in a research report released on Tuesday, The Fly reports. Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald increased their price target on shares of Amedisys from $91.00 to $100.00 in a report on […]